MK-0873
Based on 1 Customer Validation
MK-0873 is a selective phosphodiesterase-4 (PDE4) inhibitor with an IC50 value of < 38 nM. MK-0873 inhibits LPS-induced TNF-α production. MK-0873 suppresses bronchoconstriction. MK-0873 is applicable to research related to chronic obstructive pulmonary disease, plaque psoriasis and asthma.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 95.0%
- No. CAS: 500355-52-2
- Fòrmula: C25H18N4O3
- Peso molecular:422.44
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Ver todos los productos específicos de isoformas TNF Receptor
More
Actividad biológica
|
PDE4 ＜38 nM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | IC50 |
65.7 μM
Compound: 20, MK-0873
|
Displacement of [35S]MK-499 from human ERG expressed in HEK293 cells
Displacement of [35S]MK-499 from human ERG expressed in HEK293 cells
|
[PMID: 18835163] |
| Sf9 | IC50 |
6.7 nM
Compound: 20, MK-0873
|
Intrinsic inhibition of GST-fused human PDE4A expressed in SF9 cells
Intrinsic inhibition of GST-fused human PDE4A expressed in SF9 cells
|
[PMID: 18835163] |
MK-0873 is a selective PDE4 inhibitor that potently inhibits PDE-4 isoforms with IC50 values <38 nM and shows negligible activity against other PDE enzymes (IC50 >6 μM)[1].
MK-0873 potently inhibits human GST-PDE4A248 with an IC50 of 6.7 nM[3].
MK-0873 inhibits LPS-induced TNF-α production in human whole blood with an IC50 of 178 nM[3].
MK-0873 inhibits LPS-induced TNF-α production in squirrel monkey whole blood with an IC50 of 23 nM[3].
MK-0873 binds to hERG potassium channels from stably transfected HEK293 cells with an IC50 of 66 μM, showing low affinity[3].
MK-0873 weakly inhibits cytochrome P450 2C9 with an IC50 of 41 μM[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MK-0873 (0.03 mg/kg; i.p.; single dose) produces 65% inhibition of Ovalbumin (HY-W250978)-induced bronchoconstriction in sensitized guinea pigs[3].
MK-0873 (0.5 mg/kg/day; i.v.; daily; 4 days) produces 84% inhibition of late-phase Ascaris-induced bronchoconstriction in sensitized sheep[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:unspecified strain (conscious, sensitized, n > 5)[3]
-
Dosage:0.03 mg/kg
-
Administration:i.p.; single dose
-
Result:Produced 65% mean inhibition of ovalbumin-induced bronchoconstriction.
-
Animal Model:unspecified strain (Ascaris-sensitive)[3]
-
Dosage:0.5 mg/kg/day
-
Administration:i.v.; daily; 4 days
-
Result:Produced 84% mean inhibition of late-phase Ascaris-induced bronchoconstriction.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 500355-52-2
-
Appearance Solid
-
Peso molecular 422.44
-
Fòrmula C25H18N4O3
-
Color Off-white to light yellow
-
SMILES
O=C(C1=CN(C2=CC(C#CC3=C[N+]([O-])=CC=C3)=CC=C2)C4=NC=CC=C4C1=O)NC5CC5
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Pureza y Documentación
-
Ficha de datos (277 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Boot JD, et al. MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers. Pulmonary pharmacology & therapeutics. 2008;21(3):573-7. [Content Brief]
[2]. Rafael A, et al. Topical therapy for psoriasis: a promising future. Focus on JAK and phosphodiesterase-4 inhibitors. Eur J Dermatol. 2016 Jan-Feb;26(1):3-8. [Content Brief]
[3]. Guay D, et al. Optimization and structure-activity relationship of a series of 1-phenyl-1,8-naphthyridin-4-one-3-carboxamides: identification of MK-0873, a potent and effective PDE4 inhibitor. Bioorganic & medicinal chemistry letters. 2008 Oct 15;18(20):5554-8. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
MK-0873 Related Classifications
HY-108047 Related Classifications
Powered by Bioz